Want to see FR:OSE full AI Analyst Report?
Top Page
OSE Immunotherapeutics SA
(OSE)
Select Model
Select Model
Rating:41Neutral
Price Target:
€2.00
▼(-37.89% Downside)
Action:Reiterated
Date:09/26/26
The score is held down primarily by weak financial performance driven by a 2025 return to heavy losses and significant free cash flow burn, alongside meaningful leverage and equity erosion. Technical indicators reinforce the risk profile, with the stock in a clear downtrend and bearish momentum. Valuation is difficult to assess due to negative earnings and no dividend yield data.
Positive Factors
Immunotherapy focus
A focused immunotherapy model gives OSE a clear scientific identity across two substantial therapeutic areas. Concentrating resources on immune-system modulation can support specialized expertise and a coherent development strategy as programs advance through preclinical and clinical stages.
Negative Factors
Revenue collapse and losses
The sharp reversal from substantial 2024 revenue to a very small 2025 revenue base demonstrates unstable operating performance. Heavy losses alongside that decline weaken internal funding capacity and make it harder to sustain development investment without additional financial support.
Read all positive and negative factors
Positive Factors
Negative Factors
Immunotherapy focus
A focused immunotherapy model gives OSE a clear scientific identity across two substantial therapeutic areas. Concentrating resources on immune-system modulation can support specialized expertise and a coherent development strategy as programs advance through preclinical and clinical stages.
Read all positive factors
OSE Immunotherapeutics SA (OSE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€47.15M
Dividend YieldN/A
Average Volume (3M)146.87K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-96.25%
EPS Growth-197.89%
CountryFR
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume152,463
30 Day Avg. Volume146,866
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.25
Revenue Forecast (FY)€4.90M
OSE Immunotherapeutics SA Business Overview & Revenue Model
Company Description
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline fea...
OSE Immunotherapeutics SA Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.62M | 69.88M | 2.23M | 18.30M | 26.31M |
| Gross Profit | 2.62M | 69.88M | 2.23M | 18.30M | 26.31M |
| EBITDA | -44.81M | 41.14M | -17.50M | -13.11M | -13.72M |
| Net Income | -37.70M | 37.45M | -23.00M | -17.76M | -16.85M |
Balance Sheet | |||||
| Total Assets | 78.44M | 123.96M | 82.05M | 91.67M | 101.52M |
| Cash, Cash Equivalents and Short-Term Investments | 22.65M | 16.75M | 18.67M | 25.62M | 33.58M |
| Total Debt | 35.38M | 46.13M | 45.80M | 44.79M | 37.13M |
| Total Liabilities | 51.10M | 60.15M | 59.08M | 59.12M | 53.99M |
| Stockholders Equity | 27.34M | 63.81M | 22.82M | 32.55M | 47.89M |
Cash Flow | |||||
| Free Cash Flow | -34.13M | 48.36M | -20.00M | -18.53M | -10.39M |
| Operating Cash Flow | -34.03M | 48.44M | -19.76M | -18.25M | -9.92M |
| Investing Cash Flow | 41.35M | -46.91M | -507.00K | 26.00K | -827.00K |
| Financing Cash Flow | -6.51M | -3.46M | 13.32M | 10.27M | 14.96M |
OSE Immunotherapeutics SA Technical Analysis
Negative
3.22
Price Trends
2.63
Negative
2.99
Negative
3.54
Negative
Market Momentum
-0.15
Negative
31.78
Neutral
17.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:OSE, the sentiment is Negative. The current price of 3.22 is above the 20-day moving average (MA) of 2.14, above the 50-day MA of 2.63, and below the 200-day MA of 3.54, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 31.78 is Neutral, neither overbought nor oversold. The STOCH value of 17.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:OSE.
OSE Immunotherapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €144.54M | -2.54 | 152.56% | ― | -29.48% | 7.91% | |
47 Neutral | €189.23M | -4.07 | -29.36% | ― | 189.81% | 38.50% | |
44 Neutral | €6.89B | -16.71 | -85.88% | ― | ― | ― | |
44 Neutral | €20.14M | -0.56 | ― | ― | -19.02% | 10.39% | |
41 Neutral | €47.15M | -1.19 | -96.73% | ― | -96.25% | -197.89% | |
41 Neutral | €67.88M | -1.61 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:OSE
OSE Immunotherapeutics SA
2.00
-3.98
-66.49%
FR:IPH
Innate Pharma SA
1.29
-0.59
-31.46%
FR:ABVX
Abivax SA
78.70
-2.90
-3.55%
FR:TNG
Transgene
0.68
-0.66
-49.25%
FR:ALCLS
Cellectis SA
0.94
-2.20
-70.08%
FR:MAAT
MaaT Pharma
1.07
-3.16
-74.75%
OSE Immunotherapeutics SA Corporate Events
OSE Immunotherapeutics’ Tedopi Combo Shows Survival Gain in Phase 2 NSCLC Trial
Oct 19, 2026
OSE Immunotherapeutics reported topline Phase 2 results from the Combi-TED trial of its cancer vaccine Tedopi in metastatic non-small cell lung cancer patients who had progressed after first-line chemo-immunotherapy. The study tested Tedopi combin...
OSE Immunotherapeutics to Present at Chardan Healthcare Conference in New York
Oct 15, 2026
OSE Immunotherapeutics SA announced that its management team will participate in Chardan’s 10th Annual Healthcare Conference in New York on October 20, 2026. Chief Executive Officer Marc Le Bozec is scheduled for a fireside chat in the after...
OSE Immunotherapeutics Updates Share Capital and Voting Rights Structure
Oct 7, 2026
OSE Immunotherapeutics has reported that its share capital comprised 24,825,111 shares as of September 30, 2026, with 29,492,461 theoretical voting rights and 29,390,007 exercisable voting rights. These figures, published under French regulatory r...
OSE Immunotherapeutics Extends Cash Runway as Tedopi and Lusvertikimab Advance in Late-Stage Trials
Sep 28, 2026
OSE Immunotherapeutics reported a cash position of €11.1 million as of June 30, 2026, supported by a flexible bridge equity financing that extends its cash runway to the end of December 2026, while it courts institutional investors in the U....
OSE Immunotherapeutics’ Tedopi Lung Cancer Trial Selected for Oral Presentation at ESMO 2026
Sep 23, 2026
OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of its cancer vaccine Tedopi in metastatic non-small cell lung cancer have been selected for an oral presentation at the 2026 ESMO congress in Madrid. The study...
OSE Immunotherapeutics’ Partner Veloxis Starts Phase 2 Trial of Transplant Drug Pegrizeprument
Sep 9, 2026
OSE Immunotherapeutics announced that its licensee Veloxis Pharmaceuticals has dosed the first patient in RENGEVITY-201, a Phase 2 trial of pegrizeprument (VEL-101) for preventing organ rejection in kidney transplant recipients. The investigationa...
OSE Immunotherapeutics Updates Share Capital and Voting Rights After New Share Issuance
Sep 7, 2026
OSE Immunotherapeutics has reported an updated share capital and voting rights structure as of August 31, 2026, in line with French regulatory disclosure requirements. The company’s share capital now comprises 24,825,111 shares, reflecting t...
OSE Immunotherapeutics Showcases Lead IBD Drug Lusvertikimab in Upcoming KOL Webcast
Aug 28, 2026
OSE Immunotherapeutics will host a key opinion leader webcast on September 2, 2026, to highlight its lead inflammatory bowel disease candidate lusvertikimab and its role in IL-7R biology. The event will review promising Phase 2 CoTiKis trial resul...
OSE Immunotherapeutics Updates Share Capital and Voting Rights After New Equity Issuance
Aug 26, 2026
OSE Immunotherapeutics has reported that its share capital comprised 24,226,111 shares as of July 31, 2026, reflecting the company’s latest capital structure. The total number of theoretical voting rights stood at 28,992,283, with 28,898,191...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.